Skip To Main Content
Sze-Pui Tsui on Muck Rack

Sze-Pui Tsui

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sze-Pui

Contact Sze-Pui, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial

|
By Kelvin Wong, Stephen Lam, Garret Leung, Natalie Chan, Tsz-Ho Kwok, Rakesh Sharma Verified, Jason Wong, Suet-Yi Leung, Cheuk-Him Man, Li-Chuan Zheng, Chenqinyao Li, Kwui-Wa Tong, Xiao-yuan Zeng, Koon-Chuen Chan, Ka-Lam Ng, Chee-Chean Dang, Sze-Pui Tsui, Anskar Y. H. Leung
| Nature Verified
Abstract FLT3-ITD inhibitors are approved for acute myeloid leukemia (AML) treatment but relapse is common. In this study, the combined inhibition of FLT3-ITD signal and protein translation by QUIZartinib and Omacetaxine Mepesuccinate (QUIZOM) synergistically suppressed the most critical FLT3-ITD survival signals including mitochondrial respiration and proteostasis, which induced apoptosis and pro-inflammatory response.
Open in Who Shared Issue with article?
See all 1 articles